Mon, Jun 03, 2019 - Page 5 News List

New breast cancer drug sees survival rates rise by 30%

AFP, CHICAGO

A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday, citing the results of an international clinical trial.

The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70 percent after three-and-a-half years.

The mortality rate was 29 percent less than when patients, all under 59 and pre-menopausal, were randomly assigned a placebo.

Lead author Sara Hurvitz said the study focused on a form of breast cancer that is fueled by the hormone estrogen and which accounts for two-thirds of all cases among younger women.

It is generally treated by therapies that block the hormone’s production.

“You actually can get synergy, or a better response, better cancer kill, by adding one of these cell-cycle inhibitors” on top of the hormone blocking therapy, Hurvitz said.

The drug works by inhibiting the activity of cancer-cell promoting enzymes. The treatment is less toxic than traditional chemotherapy, because it more selectively targets cancerous cells, blocking their ability to multiply.

Though advanced breast cancer is less common among younger women, its incidence grew 2 percent per year in the US between 1978 and 2008 for women aged 20 to 39, a previous study showed.

The new trial, which looked at more than 670 cases, included only women who had advanced cancer — stage four — for which they had not received prior hormone-blocking therapy.

“These are patients who tend to be diagnosed later, at a later stage in their disease, because we don’t have great screening modalities for young women,” Hurvitz said.

In addition, patients who develop breast cancer early tend to have more complex cases.

A pill is administered daily for 21 days followed by seven days off to allow the body time to recover, since two-thirds of patients have a moderate to severe drop in white cell count.

Jamie Bennett, a spokeswoman for Novartis, which markets the drug under the brand name Kisqali and funded the research, said it cost US$12,553 for a 28-day dose.

There is no cure for metastatic breast cancer and the majority of the women on the drug will require some form of therapy for the rest of their lives.

Oncologist Harold Burstein of the Dana-Farber Cancer Institute in Boston, who was not involved in the research, said it was “an important study,” having established that the use of the drug “translates into a significant survival benefit for women.”

“Hopefully, these data will enable access for this product for more women around the world, particularly in healthcare systems which assess value rigorously as part of their decisions for national access to drugs,” Burstein added.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top